{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Licensed+comparator",
    "query": {
      "intervention": "Licensed comparator"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 34,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Licensed+comparator&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T09:54:58.204Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02914275",
      "title": "A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "Seqirus Quadrivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Comparator Quadrivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "59 Months",
        "sex": "ALL",
        "summary": "6 Months to 59 Months"
      },
      "enrollment_count": 2250,
      "start_date": "2016-09-27",
      "completion_date": "2017-08-11",
      "has_results": true,
      "last_update_posted_date": "2019-01-23",
      "last_synced_at": "2026-09-03T09:54:58.204Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02914275"
    },
    {
      "nct_id": "NCT05044195",
      "title": "A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "aQIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Comparator QIV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "50 Years to 64 Years"
      },
      "enrollment_count": 2044,
      "start_date": "2021-09-30",
      "completion_date": "2022-09-09",
      "has_results": true,
      "last_update_posted_date": "2023-09-28",
      "last_synced_at": "2026-09-03T09:54:58.204Z",
      "location_count": 12,
      "location_summary": "Mobile, Alabama • Tempe, Arizona • Atlantis, Florida + 9 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Atlantis",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05044195"
    },
    {
      "nct_id": "NCT00735475",
      "title": "A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "CSL Limited Influenza Virus Vaccine (Afluria®)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "US Licensed Influenza Virus Vaccine (Fluzone®)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 1268,
      "start_date": "2008-10",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2018-05-23",
      "last_synced_at": "2026-09-03T09:54:58.204Z",
      "location_count": 13,
      "location_summary": "Mountain Home, Arkansas • Boise, Idaho • Iowa City, Iowa + 10 more",
      "locations": [
        {
          "city": "Mountain Home",
          "state": "Arkansas"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Bardstown",
          "state": "Kentucky"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00735475"
    },
    {
      "nct_id": "NCT05501561",
      "title": "Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "Experimental: IIV-A Investigational IIV-A administered as a single dose intramuscularly on Day 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Experimental: aIIV-B Investigational aIIV-B administered as a single dose intramuscularly on Day 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Experimental: aIIV-C Investigational aIIV-C administered as a single dose intramuscularly on Day 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Active Comparator: Licensed IIV IIV administered as a single dose intramuscularly on Day 1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1056,
      "start_date": "2022-08-25",
      "completion_date": "2023-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-09-03T09:54:58.204Z",
      "location_count": 47,
      "location_summary": "Tempe, Arizona • Huntington Beach, California • San Diego, California + 42 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Milford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05501561"
    },
    {
      "nct_id": "NCT05645042",
      "title": "Transcendental Meditation in Veterans and First Responders With PTSD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "PTSD"
      ],
      "interventions": [
        {
          "name": "Transcendental Meditation (TM)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Present Centered Therapy (PCT)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Research Foundation for Mental Hygiene, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 55,
      "start_date": "2022-12-12",
      "completion_date": "2024-10-30",
      "has_results": false,
      "last_update_posted_date": "2025-04-09",
      "last_synced_at": "2026-09-03T09:54:58.204Z",
      "location_count": 5,
      "location_summary": "La Jolla, California • Los Angeles, California • Palo Alto, California + 2 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Great Neck",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05645042"
    },
    {
      "nct_id": "NCT03267537",
      "title": "Non-inferiority Study of Telemedicine Versus Conventional CBT-I in Recently Hospitalized Patients With Insomnia",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Insomnia"
      ],
      "interventions": [
        {
          "name": "Telemedicine CBT-I",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Conventional office-based CBT-I",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2017-06-13",
      "completion_date": "2019-05-31",
      "has_results": false,
      "last_update_posted_date": "2017-09-01",
      "last_synced_at": "2026-09-03T09:54:58.204Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03267537"
    },
    {
      "nct_id": "NCT02545543",
      "title": "A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "Seqirus QIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Comparator QIV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 2278,
      "start_date": "2015-09",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2018-05-23",
      "last_synced_at": "2026-09-03T09:54:58.204Z",
      "location_count": 32,
      "location_summary": "Huntsville, Alabama • Madera, California • Ontario, California + 29 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "Ontario",
          "state": "California"
        },
        {
          "city": "Redding",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02545543"
    },
    {
      "nct_id": "NCT00856297",
      "title": "Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Meningococcal Meningitis"
      ],
      "interventions": [
        {
          "name": "MenACWY-CRM conjugate vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Licensed comparator",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Vaccines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "11 Years to 18 Years"
      },
      "enrollment_count": 389,
      "start_date": "2009-02",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2017-06-14",
      "last_synced_at": "2026-09-03T09:54:58.204Z",
      "location_count": 32,
      "location_summary": "Birmingham, Alabama • Fremont, California • Fresno, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Hayward",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00856297"
    },
    {
      "nct_id": "NCT00764790",
      "title": "Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Fluarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "35 Months",
        "sex": "ALL",
        "summary": "6 Months to 35 Months"
      },
      "enrollment_count": 3317,
      "start_date": "2008-10-01",
      "completion_date": "2009-06-01",
      "has_results": true,
      "last_update_posted_date": "2018-07-31",
      "last_synced_at": "2026-09-03T09:54:58.204Z",
      "location_count": 62,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 58 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Benton",
          "state": "Arkansas"
        },
        {
          "city": "Conway",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00764790"
    },
    {
      "nct_id": "NCT04825223",
      "title": "Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Meningococcal Immunisation",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Multicomponent Meningococcal B Vaccine",
          "type": "DRUG"
        },
        {
          "name": "Meningococcal Group B Vaccine MenB",
          "type": "DRUG"
        },
        {
          "name": "Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "42 Days to 50 Years"
      },
      "enrollment_count": 576,
      "start_date": "2021-03-29",
      "completion_date": "2022-07-22",
      "has_results": false,
      "last_update_posted_date": "2025-10-10",
      "last_synced_at": "2026-09-03T09:54:58.204Z",
      "location_count": 8,
      "location_summary": "Guntersville, Alabama • San Diego, California • Tampa, Florida + 5 more",
      "locations": [
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "El Dorado",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04825223"
    }
  ]
}